Scinopharm Taiwan Ltd, based in Taiwan, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for A leading process R&D and API Manufacturing service provider to the Global Pharmaceutical Industry.
One of their notable products is ROFLUMILAST, with a corresponding US DMF Number 26764.
Remarkably, this DMF maintains an Active status since its submission on December 27, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 08, 2014, and payment made on March 13, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II